Spyre Therapeutics, Inc. SYRE Free cash flow
Discontinued — last reported Q4 '24
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
The official record: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s free cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported free cash flow of -$39.35M in Q4 2024.
- How has Spyre Therapeutics, Inc.'s free cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s free cash flow decreased by 26.8% year-over-year, from -$31.04M to -$39.35M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s free cash flow?
- Over 2 years (2021 to 2024), Spyre Therapeutics, Inc.'s free cash flow has grown at a 67.1% compound annual growth rate (CAGR), from -$56.34M to -$157.41M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.